Clinical Trials Browser

Phase 3 × Smoldering Multiple Myeloma × 30 days × Clear all

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT07393282 2026-03-16

LINKER-SMM2

Phase 3 Not yet recruiting

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03937635 2026-03-02

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Phase 3 Recruiting

Smoldering Multiple Myeloma